In
the
rapidly
evolving
pharmaceutical
industry,
Lifecycle
Management
(LCM)
strategies
are
critical
for
maximizing
profitability
and
extending
market
life
of
drugs.
This
study
investigates
strategic
importance
expanding
indications
sodium-glucose
cotransporter
2
(SGLT2)
inhibitors
before
expiration
their
foundational
patents.
By
analyzing
these
pre-expiration
strategies,
balance
between
genuine
innovation
evergreening
is
addressed.
The
analysis
covers
legal,
regulatory,
clinical
dimensions
indication
expansions
across
US,
EU,
Japan,
contrasting
with
traditional
focus
on
LCM
post-patent
expiration.
Diabetes Obesity and Metabolism,
Journal Year:
2024,
Volume and Issue:
26(7), P. 2787 - 2795
Published: April 15, 2024
Abstract
Aim
Sodium‐glucose
cotransporter
2
inhibitors
(SGLT2is)
and
glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1RAs)
improve
glycaemic
control
cardio‐renal
outcomes
for
people
with
type
diabetes
(T2D).
However,
geographic
socio‐economic
variation
in
use
is
not
well
understood.
Methods
We
identified
367
829
New
South
Wales
residents
aged
≥40
years
who
dispensed
metformin
2020
as
a
proxy
T2D.
estimated
the
prevalence
of
other
glucose‐lowering
medicines
among
T2D
SGLT2i
GLP‐1RA
using
concomitant
therapy
(i.e.
+
another
medicine).
measured
by
small‐level
geography,
stratified
age
group,
characterized
remoteness
status.
Results
The
(29.7%)
(8.3%)
40‐64
increased
areas
greater
disadvantage,
similar
to
medicines.
(55.4%)
(15.4%)
varied
across
areas,
lower
more
disadvantaged
localized
high
(2.5
times
median).
Compared
years,
was
older
groups,
but
patterns
areas.
Conclusions
probably
reflecting
combination
system‐
prescriber‐level
factors.
Socio‐economic
overshadowed
prescribing.
Continued
monitoring
can
help
shape
interventions
optimize
would
benefit
most.
Kidney International Reports,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 1, 2024
The
Northern
Territory
(NT)
is
a
hotspot
for
chronic
kidney
disease
(CKD)
and
has
high
incidence
of
replacement
therapy
(KRT).
Kidney
Care
clinical
decision
support
(CDS)
tool
aims
to
improve
diagnosis
management
CKD
in
remote
NT,
particularly
among
First
Nations
Australians.
We
model
the
cost-effectiveness
CDS
versus
usual
care.
Taking
health
care
funder
perspective,
we
modeled
cohort
people
from
NT
at
risk
or
with
CKD,
as
January
1,
2017.
A
Markov
was
developed
using
6
years
observed
patient-level
data
(2017-2023),
extrapolated
15-year
time
horizon.
(scenario
1),
2),
both
3).
consisted
23,195
people,
predominantly
(89%)
Nations,
mean
age
42
years.
Scenario
3
(improved
management)
most
cost-effective
an
incremental
ratio
(ICER)
$96,684
per
patient
avoiding
KRT,
$30,086
death.
1
diagnosis)
less
cost-effective,
scenario
2
least
cost-effective.
ICER
quality-adjusted
life
(QALYs)
gained
ranged
$3427
3)
$63,486
2).
highly
when
it
supports
early
increases
optimal
diagnosed
patients.
These
results
investing
tools,
implemented
strong
partnerships,
outcomes
settings
burden
CKD.
In
the
rapidly
evolving
pharmaceutical
industry,
Lifecycle
Management
(LCM)
strategies
are
critical
for
maximizing
profitability
and
extending
market
life
of
drugs.
This
study
investigates
strategic
importance
expanding
indications
sodium-glucose
cotransporter
2
(SGLT2)
inhibitors
before
expiration
their
foundational
patents.
By
analyzing
these
pre-expiration
strategies,
balance
between
genuine
innovation
evergreening
is
addressed.
The
analysis
covers
legal,
regulatory,
clinical
dimensions
indication
expansions
across
US,
EU,
Japan,
contrasting
with
traditional
focus
on
LCM
post-patent
expiration.
